Biovie is trading at $1.64, up 6.37%, with no clear company-specific catalyst identified for the September 30 pre-market rise. - A September 29 DEF 14A filing was reported, but available coverage provides no material announcement explaining the move. - Phase 2 Long COVID trial results were announced September 15; this was not a new overnight announcement. - Major-index moves were modest and mixed, offering no clear broader-market explanation; the reason remains unclear.